表柔比星用于既往未经治疗的小细胞肺癌患者：欧洲癌症研究与治疗组织肺癌协作组的一项II期研究

Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative Group.

作者信息

Quoix E A, Giaccone G, Jassem J, Karnicka H, Wiatr E, Cortes-Funes H, Roozendaal K J, Kirkpatrick A, Evrard D, van Zandwijk N

机构信息

Pavillon Laennec, Hôpitaux Universitaires de Strasbourg, France.

出版信息

Eur J Cancer. 1992;28A(10):1667-70. doi: 10.1016/0959-8049(92)90065-a.

DOI:10.1016/0959-8049(92)90065-a

PMID:1327019

Abstract

Epirubicin 110 mg/m2 was administered intravenously every 3 weeks to 41 elderly and/or unfit, previously untreated patients with small cell lung cancer (SCLC). There were three complete responses, 16 partial responses and 14 treatment failures, with a response rate of 57% in 33 evaluable patients. The main toxicity was haematological, characterised by leukopenia and, less frequently, thrombocytopenia and anaemia. There were three toxic deaths due to infection occurring during leukopenia. Non-haematological side effects were alopecia, nausea, stomatitis and diarrhoea. WHO grade 2 cardiac toxicity was seen in 3 patients after a cumulative dose of more than 740 mg/m2. In conclusion epirubicin is an active agent in untreated SCLC.

摘要

对41例老年和/或身体状况不佳、既往未接受过治疗的小细胞肺癌（SCLC）患者，每3周静脉注射表柔比星110mg/m²。有3例完全缓解，16例部分缓解，14例治疗失败，33例可评估患者的缓解率为57%。主要毒性为血液学毒性，表现为白细胞减少，较少见血小板减少和贫血。有3例因白细胞减少期间发生感染导致的毒性死亡。非血液学副作用有脱发、恶心、口腔炎和腹泻。3例患者在累积剂量超过740mg/m²后出现世界卫生组织2级心脏毒性。总之，表柔比星是未治疗的小细胞肺癌的一种有效药物。